High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial

BACKGROUND: Post COVID-19 condition (PCC) is defined as symptoms lasting more than 12 weeks after developing COVID-19. Evidence of mitochondrial dysfunction has been reported in peripheral blood mononuclear cells obtained from patients with COVID-19. We hypothesized that PCC is caused by prolonged m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Kristoffer S., Mogensen, Trine H., Agergaard, Jane, Schiøttz-Christensen, Berit, Østergaard, Lars, Vibholm, Line K., Leth, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627534/
https://www.ncbi.nlm.nih.gov/pubmed/36337437
http://dx.doi.org/10.1016/j.lanepe.2022.100539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627534/
https://www.ncbi.nlm.nih.gov/pubmed/36337437
http://dx.doi.org/10.1016/j.lanepe.2022.100539

Ejemplares similares